Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
Trade-Ideas LLC identified
) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Immunomedics as such a stock due to the following factors:
- IMMU has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $2.8 million.
- IMMU has traded 85,661 shares today.
- IMMU is trading at 3.37 times the normal volume for the stock at this time of day.
- IMMU is trading at a new high 3.13% above yesterday's close.
'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in IMMU with the Ticky from Trade-Ideas. See the FREE profile for IMMU NOW at Trade-Ideas
More details on IMMU:
Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases in the United States. Currently there are 3 analysts that rate Immunomedics a buy, no analysts rate it a sell, and none rate it a hold.
The average volume for Immunomedics has been 503,100 shares per day over the past 30 days. Immunomedics has a market cap of $317.5 million and is part of the health care sector and drugs industry. The stock has a beta of 0.77 and a short float of 18.3% with 16.03 days to cover. Shares are down 23.5% year-to-date as of the close of trading on Friday.
rates Immunomedics as a
. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself.
Highlights from the ratings report include:
- IMMUNOMEDICS INC's earnings per share declined by 44.4% in the most recent quarter compared to the same quarter a year ago. Earnings per share have declined over the last two years. We anticipate that this should continue in the coming year. During the past fiscal year, IMMUNOMEDICS INC reported poor results of -$0.41 versus -$0.15 in the prior year. For the next year, the market is expecting a contraction of 18.3% in earnings (-$0.49 versus -$0.41).
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 54.2% when compared to the same quarter one year ago, falling from -$7.68 million to -$11.85 million.
- Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Biotechnology industry and the overall market, IMMUNOMEDICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
- Net operating cash flow has decreased to -$9.33 million or 43.69% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
- Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 44.29%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 44.44% compared to the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
- You can view the full Immunomedics Ratings Report.